Lanadelumab in Hereditary Angioedema: Real-World Outcomes and Implications for Access Practices in Europe
Dagmara Różyk, Witold Wrona, Barbara Kucharczyk, Agata Tomaszewska, Aleksandra Kucharczyk · 2025
Read Lanadelumab in Hereditary Angioedema: Real-World Outcomes and Implications for Access Practices in Europe by Dagmara Różyk, Witold Wrona, Barbara Kucharczyk, Agata Tomaszewska, Aleksandra Kucharczyk (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12786760.txt.
Description
Różyk and co-authors report real-world results for a preventive drug in hereditary angioedema across Europe. The condition causes sudden swelling attacks, and lanadelumab is approved to prevent them. Trial results look strong, but data on payment rules and daily practice are scarce. The team studied 72 patients in Poland's drug program, all lacking a key inhibitor protein. Follow-up ran a median of 20 months.
Records captured attack rates and rescue drug use before and after at least six months on the drug. The team also compared payment rules across European countries. That comparison shows how proof of benefit shapes who gets access. The study links clinical results to the policies that gate them.
Catalog record
| CREATOR | Dagmara Różyk, Witold Wrona, Barbara Kucharczyk, Agata Tomaszewska, Aleksandra Kucharczyk |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |